Cancer Research Technology
Log in Register
Menu

CCRF-CEM-R5 Cell line

Invented by Aintzane Asumendi, at University of the Basque Country, EHU Aintzane Apraiz, at University of the Basque Country, EHU Dolores Boyano at University of the Basque Country, EHU

Info

Antigen/Gene or Protein Targets Relevant disease (Acute Lymphoblastic Leukemia/ALL); Drug (synthetic retinoid 4-HPR: fenretinide or N-(4-hydroxyphenyl)retinamide)
Parental Line CCRF-CEM
Host Human
Tissue Bone Marrow
Disease Keywords Cancer, Acute Lymphoblastic Leukemia
Model Tumour line
Relevance 4-HPR is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, including leukemia cells.
Production Details CCRF-CEM-R5 cell line, resistant to up to 5 mM of 4-HPR, was obtained by gradual selection. Parental CCRF-CEM cells were continuously exposed to increasing 4-HPR concentrations, starting from 0.5 mM.
Conditional No
Research Area Cancer, Drug Discovery & Development, Other
Growth/Phenotype Keywords Cell grow in suspension
Recommended Growing Conditions Cells should be grown in RPMI 1640 with 2mM L-glutamine supplemented with 10% heat inactivated FBS. Keep at 37ÂșC in a humidified incubator containing 5% CO2. In order to preserve their resistant intermitent exposures to 5mM 4-HPR is recomended. 4-HPR removal from R5 cell culture for up to 8 passages or 3 weeks has not shown any decrease on drug resistance although it does affect endogenous sphingolipid profile (specified in the reference paper).
Positive Control Control cells are CCRF-CEM parental cells that are sensitive to higher than 1mM 4HPR

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Apraiz et al. 2011. BMC Cancer. 11:477. PMID: 22061047.


Add a reference

References: 1 entry

Apraiz et al. 2011. BMC Cancer. 11:477. PMID: 22061047.


Add a reference

Inventor Information

Inventors

Aintzane Asumendi

Aintzane Asumendi

Aintzane Apraiz

Aintzane Apraiz

Dolores Boyano

Dolores Boyano

Add an inventor